532 A. L. Alessandri et al. Infl amm. res.
and dropped to baseline levels after specifi c treatment. The
present study did not measure chemokines and sTNFR1 in a
longitudinal manner and lacked a longer follow-up period.
Moreover and due to our selection of HIV-negative patients,
it only included patients who responded to conventional tu-
berculostatic chemotherapy. Despite the latter limitations, it
is apparent that measurement of these proteins may be useful
to assess response to treatment in pulmonary TB patients.
Further studies in the general population and in patients who
fail treatment are necessary to support this possibility.
Acknowledgments. This investigation received fi nancial support from the
UNICEF/UNDP/World Bank/WHO Special Programme for Research
and Training in Tropical Diseases (TDR A20748), Conselho Nacional de
Desenvolvimento Científi co e Tecnológico (CNPq, Brazil) and Fundação
do Amparo a pesquisas do Estado de Minas Gerais (FAPEMIG, Brazil).
References
[1] World Health Organization (WHO). The double burden: emerg-
ing epidemics and persistent problems. In: The world health report
1999: making a difference. Geneva: WHO; 1999: 13–28.
[2] Chensue SW, Warmington K, Ruth J, Lincoln P, Kuo MC, Kunkel
SL. Cytokine responses during mycobacterial and schistosomal an-
tigen-induced pulmonary granuloma formation. Production of Th1
and Th2 cytokines and relative contribution of tumor necrosis fac-
tor. Am J Pathol 1994; 145: 1105–13.
[3] Chiu BC, Freeman CM, Stolberg VR, Komuniecki E, Lincoln PM,
Kunkel SL et al. Cytokine-chemokine networks in experimental
mycobacterial and schistosomal pulmonary granuloma formation.
Am J Respir Cell Mol Biol 2003; 29: 106–16.
[4] Ladel CH, Szalay G, Riedel D, Kaufmann SH. Interleukin-12 se-
cretion by Mycobacterium tuberculosis-infected macrophages. In-
fect Immun 1997; 65: 1936–8.
[5] Qiu B, Frait KA, Reich F, Komuniecki E, Chensue SW. Chemokine
expression dynamics in mycobacterial (type-1) and schistosomal
(type-2) antigen-elicited pulmonary granuloma formation. Am J
Pathol 2001; 158: 1503–15.
[6] Serbina NV, Flynn JL. Early emergence of CD8(+) T cells primed
for production of type 1 cytokines in the lungs of Mycobacterium
tuberculosis-infected mice. Infect Immun 1999; 67: 3980–8.
[7] Taha RA, Minshall EM, Olivenstein R, Ihaku D, Wallaert B, Tsico-
poulos A, Tonnel AB, Damia R, Menzies D, Hamid QA. Increased
expression of IL-12 receptor mRNA in active pulmonary tuber-
culosis and sarcoidosis. Am J Respir Crit Care Med 1999; 160:
1119–23.
[8] Van Crevel R, Ottenhoff TH, Van Der Meer JW. Innate immunity to
Mycobacterium tuberculosis. Clin Microbiol Rev 2002; 15: 294–
309.
[9] Murphy PM, Baggiolini M, Charo IF, Hebert CA, Horuk R, Mat-
sushima K et al. International union of pharmacology. XXII. No-
menclature for chemokine receptors. Pharmacol Rev 2000; 52:
145–76.
[10] Lee JS, Song CH, Lim JH, Lee KS, Kim HJ, Park JK et al. Mono-
cyte chemotactic protein-1 production in patients with active pul-
monary tuberculosis and tuberculous pleurisy. Infl amm. Res 2003;
52: 297–304.
[11] Sadek MI, Sada E, Toossi Z, Schwander SK, Rich EA.Chemokines
induced by infection of mononuclear phagocytes with mycobacte-
ria and present in lung alveoli during active pulmonary tuberculo-
sis. Am J Respir Cell Mol Biol 1998; 19: 513–21.
[12] Zhang Y, Broser M, Cohen H, Bodkin M, Law K, Reibman J et
al. Enhanced interleukin-8 release and gene expression in macro-
phages after exposure to Mycobacterium tuberculosis and its com-
ponents. J Clin Invest 1995; 95: 586–92.
[13] Seiler P, Aichele P, Bandermann S, Hauser AE, Lu B, Gerard NP et
al. Early granuloma formation after aerosol Mycobacterium tuber-
culosis infection is regulated by neutrophils via CXCR3-signaling
chemokines. Eur J Immunol 2003; 33: 2676–86.
[14] Juffermans NP, Verbon A, Van Deventer SJ, Van Deutekom H,
Belisle JT, Ellis ME et al. Elevated chemokine concentrations in
sera of human immunodefi ciency virus (HIV)-seropositive and
HIV-seronegative patients with tuberculosis: a possible role for
mycobacterial lipoarabinomannan. Infect Immun 1999; 67: 4295–
7.
[15] Kurashima K, Mukaida N, Fujimura M, Yasui M, Nakazumi Y,
Matsuda T et al. Elevated chemokine levels in bronchoalveolar lav-
age fl uid of tuberculosis patients. Am J Respir Crit Care Med 1997;
155: 1474–7.
[16] Ribeiro-Rodrigues R, Co RT, Johnson JL, Ribeiro F, Palaci M, Sa
RT et al. Sputum cytokine levels in patients with pulmonary tuber-
culosis as early markers of mycobacterial clearance. Clin Diagn
Lab Immunol 2002; 9: 818–23.
[17] Mitchison DA. Assessment of new sterilizing drugs for treating
pulmonary tuberculosis by culture at 2 months. Am Rev Respir Dis
1993; 147: 1062–3.
[18] Kawaguchi H, Ina Y, Ito S, Sato S, Sugiura Y, Tomita H et al. Serum
levels of solubule tumor necrosis factor (TNF) receptors in patients
with pulmonary tuberculosis. Kekkaku 1996; 71: 259–65.
[19] Mastroianni CM, Paoletti F, Lichtner M, D’Agostino C, Vullo V,
Delia S. Cerebrospinal fl uid cytokines in patients with tuberculous
meningitis. Clin Immunol Immunopathol 1997; 84: 171–6.
[20] Falcão PL, Correa-Oliveira R, Fraga LA, Talvani A, Proudfoot AE,
Wells TN et al. Plasma concentrations and role of macrophage in-
fl ammatory protein-1alpha during chronic Schistosoma mansoni
infection in humans. J Infect Dis 2002; 186: 1696–1700.
[21] Souza ALS, Roffê E, Pinho V, Souza DG, Silva AF, Russo RC et al.
The potential role of the chemokine macrophage infl ammatory pro-
tein-1a (MIP-1a/CCL3) in human and experimental schistosomia-
sis. Infect Immun 2006; 73: 2515–23.
[22] Teixeira AL Jr, Cardoso F, Souza AL, Teixeira MM. Increased
serum concentrations of monokine induced by interferon-gamma/
CXCL9 and interferon-gamma-inducible protein 10/CXCL-10 in
Sydenham’s chorea patients. J Neuroimmunol 2004; 150: 157–62.
[23] Algood HM, Chan J, Flynn JL. Chemokines and tuberculosis. Cy-
tokine Growth Factor Rev 2003; 14: 467–7.
[24] Peters W, Ernst JD. Mechanisms of cell recruitment in the immune
response to Mycobacterium tuberculosis. Microbes Infect 2003; 5:
151–8.
[25] Perez RL, Rivera-Marrero CA, Roman J. Pulmonary granuloma-
tous infl ammation: From sarcoidosis to tuberculosis. Semin Respir
Infect 2003; 18: 23–32.
[26] Azzurri A, Sow OY, Amedei A, Bah B, Diallo S, Peri G et al. IFN-
gamma-inducible protein 10 and pentraxin 3 plasma levels are tools
for monitoring infl ammation and disease activity in Mycobacteri-
um tuberculosis infection. Microbes Infect. 2005; 7: 1–8.
[27] Miotto D, Christodoulopoulos P, Olivenstein R, Taha R, Cameron
L, Tsicopoulos A et al. Expression of IFN-gamma-inducible pro-
tein; monocyte chemotactic proteins 1, 3, and 4; and eotaxin in
TH1- and TH2-mediated lung diseases. J Allergy Clin Immunol
2001; 107: 664–70.
[28] Ragno S, Romano M, Howell S, Pappin DJ, Jenner PJ, Colston MJ.
Changes in gene expression in macrophages infected with Myco-
bacterium tuberculosis: a combined transcriptomic and proteomic
approach. Immunology 2001; 104: 99–108.
[29] Weng Y, Siciliano SJ, Waldburger KE, Sirotina-Meisher A, Staruch
MJ, Daugherty BL et al. Binding and functional properties of re-
combinant and endogenous CXCR3 chemokine receptors. J Biol
Chem 1998; 17: 18288–91.
[30] Gear AR, Camerini D. Platelet chemokines and chemokine recep-
tors: linking hemostasis, infl ammation, and host defense. Microcir-
culation 2003; 10: 335–50.
[31] Struyf S, Burdick MD, Proost P, Van Damme J, Strieter RM. Plate-
lets release CXCL4L1, a nonallelic variant of the chemokine plate-
let factor-4/CXCL4 and potent inhibitor of angiogenesis. Circ Res
2004; 95: 855–7.